HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD Keeps An Eye On Anti-Aging Claims With Olay Regenerist Inquiry

This article was originally published in The Rose Sheet

Executive Summary

The National Advertising Division of the Council of Better Business Bureaus recommended Procter & Gamble modify ads for Olay Regenerist Eye Lifting Serum that imply the product can produce results similar to eyelift surgery following a recent inquiry

You may also be interested in...



Comparing Eyetuck To Surgery Is More Than Mere Puffery – NAD

Skin Doctors Cosmeceuticals should "limit its performance claims to the efficacy of the ingredient Eyeseryl" when touting its Eyetuck Anti-Bag Technology product for potential reduction of under eye puffiness, the National Advertising Division (NAD) concludes in an upcoming Case Reports

Comparing Eyetuck To Surgery Is More Than Mere Puffery – NAD

Skin Doctors Cosmeceuticals should "limit its performance claims to the efficacy of the ingredient Eyeseryl" when touting its Eyetuck Anti-Bag Technology product for potential reduction of under eye puffiness, the National Advertising Division (NAD) concludes in an upcoming Case Reports

P&G Discontinues Olay Regenerist Ad With “Inadequate” Disclaimer

Procter & Gamble has permanently discontinued a print ad for Olay Regenerist Night following an inquiry by the National Advertising Division of the Council of Better Business Bureaus, the agency says in a recent Case Reports

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel